nct_id: NCT06153238
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2023-12-01'
study_start_date: '2024-05-15'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Keytruda - US'
  - drug_name: 'Drug: GME751'
  - drug_name: 'Drug: Keytruda - EU'
long_title: "A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics\
  \ of GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU Authorized\
  \ Keytruda\xAE in Participants With Stage II and III Melanoma Requiring Adjuvant\
  \ Treatment With Pembrolizumab"
last_updated: '2025-07-09'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Sandoz
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 318
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* At least 18 years of age'
- '* Advanced Melanoma'
- '* Completely removed melanoma by surgery performed within 13 weeks of randomization'
- '* Adequate organ function'
- '* Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score
  of 0 or 1'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Known history or evidence of ocular or uveal melanoma
- "Exclude - * Known history of hypersensitivity (grade \u22653) to pembrolizumab\
  \ or its excipients"
- Exclude - * Known History of auto-immune disease
- "Exclude - * Received live vaccine \u226430 days before the first study treatment"
- Exclude - * Prior treatment with anti-PD-1 agents or agent against another stimulatory
  or co-inhibitory T cell receptor
- Exclude - * Active autoimmune disease that has necessitated chronic systemic treatment
  within 2 years before the first study treatment
- Exclude - Other protocol-defined inclusion/exclusion criteria apply
short_title: "A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and\
  \ US-licensed and EU-authorized Keytruda\xAE in Participants With Stage II and III\
  \ Melanoma"
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Sandoz
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "The purpose of this study is to investigate the pharmacokinetic (PK) similarity\
  \ and efficacy, safety, and immunogenicity of GME751 compared with Keytruda\xAE\
  \ (pembrolizumab) in subjects with resected advanced melanoma requiring adjuvant\
  \ treatment with pembrolizumab."
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: GME751
      arm_internal_id: 0
      arm_description: Subjects will receive GME751 via intravenous (IV) infusion.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: GME751'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Keytruda - EU
      arm_internal_id: 1
      arm_description: Subjects will receive Keytruda-EU via intravenous (IV) infusion.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Keytruda - EU'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Keytruda - US
      arm_internal_id: 2
      arm_description: Subjects will receive Keytruda-US via intravenous (IV) infusion.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Keytruda - US'
        level_internal_id: 0
        level_suspended: N
    match:
    - clinical:
        age_numerical: '>=18'
        disease_status:
        - Advanced
        oncotree_primary_diagnosis: Melanoma
